News
SNY
49.28
-0.17%
-0.09
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Annual Meeting of the American Society of Clinical Oncology will be held in Chicago. The oral presentations will cover a range of topics including targeted therapies and immunologic therapies for various types of cancer. The plenary session will feature presentations on esophageal cancer, melanoma and lung cancer.
Seeking Alpha · 21h ago
Bankruptcy allowed Mallinckrodt to end Acthar royalties, 3rd Circ. rules
Bankruptcy allowed Mallinckrodt to end Acthar royalties, 3rd Circ. Rules, appeals court says. Drug company acquired Acthar from Sanofi-Aventis in 2001. The best-selling medication is used to treat multiple sclerosis and infantile spasms. Sanofi argued it had right to continue selling the drug.
Reuters · 21h ago
EXPLAINER-What to know about bird flu in dairy cows and the risk to humans
First known outbreak of bird flu in dairy cows has spread to 33 herds in eight states in the U.S. Only one person has tested positive for H5N1, and the risk to humans is low. The virus has spread through the milk supply in the country's milk supply. Scientists say the virus could spread to humans.
Reuters · 22h ago
DZ BANK AG Keeps Their Hold Rating on Sanofi (SNYNF)
TipRanks · 1d ago
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
AbbVie released topline results from a head-to-head study of upadacitinib and dupilumab for atopic dermatitis. The company says the study is the first in the world to assess the effectiveness of the two drugs.
Benzinga · 1d ago
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
NASDAQ · 1d ago
Sanofi SA Starts 2024 with Strong Sales Growth
TipRanks · 1d ago
AbbVie reports positive results from Rinvoq versus Dupixent study
AbbVie reports positive results from Rinvoq versus Dupixent study. Sanofi and Regeneron's Dupixen also in the study. Abbvie says its drug is more effective in treating symptoms of moderate-to-severe atopic dermatitis.
Seeking Alpha · 1d ago
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
NASDAQ · 1d ago
BUZZ-Regeneron falls after blockbuster drug misses revenue estimates
Regeneron Pharmaceuticals falls as much as 3.3% to a 3-month low of $876.75. Sanofi partner for co's blockbuster drug, Dupixent, reports 2.84 billion euros in Q1 sales for the drug. Shares of Regeneron miss Wall Street estimates of $3.17 billion.
Reuters · 1d ago
Jefferies Sticks to Its Buy Rating for Sanofi (SNYNF)
TipRanks · 1d ago
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday
Shares of Sanofi SA rose sharply during Thursday's session following better-than-expected first-quarter earnings. The French drugmaker reported adjusted EPS of 97 cents, beating the consensus estimate of 94 cents. Sanofi shares climbed 5.5% to $49.15 on Thursday. U.S. Stocks were lower on Thursday with the Dow Jones falling over 600 points.
Benzinga · 1d ago
Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings
Benzinga · 1d ago
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie's drug, Rinvoq, found to be more effective than Regeneron's Dupixent in study. Atopic dermatitis is a type of inflammatory skin condition. Abbvie says drug helped 19.9% of patients achieve complete skin clearance after 16 weeks.
Reuters · 1d ago
REFILE-AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study
AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study. The drug, for treating a type of inflammatory skin condition, showed superior efficacy to Sanofi and Regeneron in a late-stage head-to-head study. Abbvie's drug, Rinvoqu, is being tested to treat a skin condition.
Reuters · 1d ago
SNY Earnings: Sanofi Jumps on Healthy Q1 Performance
TipRanks · 1d ago
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
The index futures are pointing to a lower opening on Thursday. Meta Platforms, Inc.’s lukewarm second-quarter revenue guidance and commentary punctured the market. The tech-heavy Nasdaq Composite and the S&P 500 Index ended Wednesday's session marginally higher. The first-quarter GDP data and personal income and spending report are due for the week.
Benzinga · 1d ago
UPDATE 1-European stocks slip as mixed earnings offset M&A cheer
European stocks slip as mixed earnings offset M&A cheer. Britain's FTSE 100 hits a record high as mining sector powers Britain's index to fresh peaks. The pan-European STOXX 600 index is down 0.1% after mixed earnings from Nestle and Deutsche Bank. Nestle down on Q1 organic sales miss, while BNP Paribas climbs on upbeat results.
Reuters · 1d ago
UPDATE 2-Sanofi profit slips on generic competition and currency effects
French drugmaker's first-quarter operating income falls 14.7% to 2.84 billion euros. Sales of Aubagio outweighed rising sales of Dupixent. Company expects 2024 adjusted earnings to slip by a low single-digit percentage. Argentine Peso decline a drag on overseas sales.
Reuters · 1d ago
UPDATE 1-Sanofi Q1 profit slips on generic competition, forex effects
Sanofi's first-quarter operating income falls 14.7% on generic competition, forex effects. French drugmaker says sales of Dupixent jumped 25% to 2.84 billion euros. Company expects 2024 adjusted earnings to slip by a "low single-digit" percentage.
Reuters · 1d ago
More
Webull provides a variety of real-time SNY stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.